Back

Choosing the most effective and safest P2Y12 Inhibitor for use in >70-year-old acute coronary syndrome patients: a network meta-analysis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Drug interactions, efficacy, and safety Antiplatelet Drugs ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Mohamed Abouzid

Poznan University of Medical Sciences, Poznan (Poland)

7 More presentations in this session

Presentation thumbnail
Adverse cardiovascular outcomes due to potential drug-drug interactions in statin therapy: a population-based study
Ms A. Lai (Shatin, HK)
Abstract Slides Video
Presentation thumbnail
Modulation of p300 acetylation to protect against doxorubicin-induced cardiotoxicity
Mr J. Lee (Toronto, CA)
Abstract Slides Video
Presentation thumbnail
Development of a cardiotoxicity evaluation system using a Heart-on-a-Chip Microdevice with aligned fiber device
Doctor K. Murata (Kobe, JP)
Abstract Slides Video
Presentation thumbnail
Drug-drug interactions of empagliflozin and dapagliflozin
Professor C. Stoellberger (Vienna, AT)
Abstract Slides Video
Presentation thumbnail
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study
Mr S. Nielsen (Hellerup, DK)
Abstract Slides Video

Access the full session

Session thumbnail
Drug interactions, efficacy, and safety

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Ticagrelor vs. clopidogrel in elderly patients following acute myocardial infarction: a multicenter international analysis
thumbnail
Congress Presentation
Clinical and peri procedural outcomes using reduced dose prasugrel vs standard dose ticagrelor in elderly patients of acute coronary syndrome undergoing PCI
thumbnail
Congress Presentation
Ticagrelor or clopidogrel in atrial fibrillation patients undergoing percutaneous coronary intervention for myocardial infarction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources